

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>REVA Medical, Inc.</b>
<b>ARBN</b>	<b>146 505 777</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert B. Thomas
<b>Date of last notice</b>	26 July 2016

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	See below
<b>Date of change</b>	25 May 2017
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>• 1,100,000 CDIs (equivalent to 110,000 shares of common stock) held by Robert Thomas and Kyrenia Thomas atf Rob Thomas Superfund A/C</li> <li>• 75,000 CDIs (equivalent to 7,500 shares of common stock) by the Tony McCullough Foundation Trust (Mr. Thomas is a trustee; however, he has no beneficial interest in the shares held by the Trust)</li> <li>• 15,000 shares of common stock (equivalent to 150,000 CDIs) held by Robert B. Thomas</li> <li>• 62,500 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$11.00 per share under the Company's 2010 Equity Incentive Plan</li> <li>• 12,500 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$6.52 per share under the Company's 2010 Equity Incentive Plan</li> <li>• 15,000 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$5.55 per share under the Company's 2010 Equity Incentive Plan</li> <li>• 15,000 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$1.50 per share under the Company's Amended and Restated 2010 Equity Incentive Plan</li> <li>• 11,800 options each to acquire 1 share of common stock at an exercise price of US\$8.90 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> </ul>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

	<ul style="list-style-type: none"> <li>6,300 restricted stock units, each for 1 share of common stock upon vesting, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> </ul>
<b>Class</b>	<ul style="list-style-type: none"> <li>CDIs (1,175,000 CDIs)</li> <li>Common Stock (15,000 shares common stock) (equivalent to 150,000 CDIs)</li> <li>Options (over 116,800 shares) (equivalent to 1,168,000 CDIs)</li> <li>Restricted stock units (over 6,300 shares ) (equivalent to 63,000 CDIs)</li> </ul>
<b>Number acquired</b>	6,300 shares of common stock (equivalent to 63,000 CDIs)
<b>Number disposed</b>	None
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	None
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>1,100,000 CDIs (equivalent to 110,000 shares of common stock) held by Robert Thomas and Kyrenia Thomas atf Rob Thomas Superfund A/C</li> <li>75,000 CDIs (equivalent to 7,500 shares of common stock) by the Tony McCullough Foundation Trust (Mr. Thomas is a trustee; however, he has no beneficial interest in the shares held by the Trust)</li> <li>21,300 shares of common stock (equivalent to 213,000 CDIs) held by Robert B. Thomas</li> <li>62,500 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$11.00 per share under the Company's 2010 Equity Incentive Plan</li> <li>12,500 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$6.52 per share under the Company's 2010 Equity Incentive Plan</li> <li>15,000 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$5.55 per share under the Company's 2010 Equity Incentive Plan</li> <li>15,000 options held by Robert B. Thomas to acquire 1 share of common stock each at an exercise price of US\$1.50 per share under the Company's Amended and Restated 2010 Equity Incentive Plan</li> <li>11,800 options each to acquire 1 share of common stock at an exercise price of US\$8.90 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Vesting of restricted stock units

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

For personal use only

**Part 3 – +Closed period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only